The clinical trial compares two advanced laser technologies for treating benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS). The Holmium Xpeeda fiber is positioned as a potentially superior alternative to the Greenlight XPS system, emphasizing efficiency and reduced operative time. The successful demonstration of improved outcomes could enhance market adoption of the Xpeeda technology, particularly in the minimally invasive surgery segment. Given the prevalence of BPH, which affects a significant portion of the male population over 50, the market potential is substantial. The results may influence purchasing decisions in urology departments and impact competitive dynamics among laser device manufacturers.